Silo Pharma, Inc. annual report, FY2012

Filing and reporting period

The supplied filing is Point Capital, Inc.’s (formerly Gold Swap Inc.) Form 10-K for the fiscal year ended December 31, 2012, filed March 5, 2013. This does not match the request metadata identifying Silo Pharma, Inc.; verify the issuer before relying on this summary.

Point Capital described itself as a development-stage company pursuing a mail-order precious-metals recycling business, but reported no revenue since its July 2010 inception and no day-to-day operations. Management was also exploring other opportunities, including becoming a business development company.

Financial results and liquidity

Operating expenses and net loss declined about 21% year over year; operating cash use declined about 54%. With no revenue, gross profit and operating margins are not meaningful. At December 31, 2012, total assets were $279, total liabilities were $41,473, working capital deficit was $25,412, and stockholders’ deficit was $41,194.

Debt included $15,000 in unsecured notes bearing 6% interest (12% upon default), due February 2014, and a $5,000 unsecured note bearing 5%, due December 2013. The company had $20,000 in note proceeds during 2012. It reported no off-balance-sheet arrangements or capital-expenditure commitments.

Material changes and notable items

• The company’s cash fell from $1,752 to $279 while accounts payable and accrued expenses rose from $3,500 to $20,691; notes payable increased to $20,000.
• A merger effective January 24, 2013 changed the company’s state of incorporation from New York to Delaware and its name from Gold Swap Inc. to Point Capital, Inc. These events occurred after the 2012 year-end.
• Former officers Melvin Schlossberg and Donald Ptalis resigned January 28, 2013. Richard A. Brand became chairman and CEO, Eric Weisblum became president, and Vadim Mats became CFO.
• The independent auditor issued an unqualified opinion on the financial statements but highlighted substantial doubt about the company’s ability to continue as a going concern. The auditor did not attest to internal-control effectiveness; management reported controls effective.

Outlook, risks, and contingencies

Management said the $279 cash balance was insufficient to fund operations for the next 12 months and disclosed no current financing agreements or arrangements. The company said it might need debt or equity financing, potentially related-party funding, and that inability to raise funds could threaten its viability. Plans were conditional on management deciding to proceed and included securing refinery agreements, soliciting customers, and earning a spread between scrap and spot prices; no revenue forecast or formal guidance was provided.

Key business risks described include early-stage execution and funding needs, dependence on refinery relationships, competition, consumer-protection and licensing requirements, and potential theft or shipping losses. The filing said insurance of up to $500 per kit was contemplated if obtainable; it did not establish that coverage was in place. The company reported no pending legal proceedings. Its approximately $93,000 net operating loss carryforward was subject to potential Section 382 limits, and deferred tax assets were fully offset by a valuation allowance.

Investor verification priorities

• Confirm the filing belongs to the intended issuer: the provided document names Point Capital, Inc., not Silo Pharma, Inc.
• Review the going-concern disclosure, cash position, working-capital deficit, and availability of committed financing.
• Verify the status of the proposed precious-metals business, refinery agreements, and management’s alternative business plans.
• Check the post-year-end merger, name change, officer departures, and resulting ownership and governance arrangements.
• Confirm the terms, balances, maturity dates, and any related-party connections of the outstanding notes.